Helixgate

Helixgate

Uncategorized

Cytokinetics succeeds where Bristol Myers failed in heart muscle disease

Published

on

Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease.

The company said Tuesday that Myqorzo …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Vertex earnings get muted investor response

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Read More

Published

on

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Read More

Continue Reading

Uncategorized

Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution

Published

on

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.

Continue Reading

Uncategorized

Foundayo’s liver failure blip weighs down Lilly shares. but analysts unconcerned

Published

on

The selloff in Eli Lilly’s shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.

Continue Reading
Advertisement

Trending